CA2805200A1 - Use of antibodies against icam-1 in the treatment of patients with relapsed cancer - Google Patents

Use of antibodies against icam-1 in the treatment of patients with relapsed cancer Download PDF

Info

Publication number
CA2805200A1
CA2805200A1 CA2805200A CA2805200A CA2805200A1 CA 2805200 A1 CA2805200 A1 CA 2805200A1 CA 2805200 A CA2805200 A CA 2805200A CA 2805200 A CA2805200 A CA 2805200A CA 2805200 A1 CA2805200 A1 CA 2805200A1
Authority
CA
Canada
Prior art keywords
antibody
cancer
antigen
icam
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2805200A
Other languages
English (en)
French (fr)
Inventor
Markus Hansson
Bjorn Frendeus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioinvent International AB
Original Assignee
Bioinvent International AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioinvent International AB filed Critical Bioinvent International AB
Publication of CA2805200A1 publication Critical patent/CA2805200A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2805200A 2010-07-13 2011-07-13 Use of antibodies against icam-1 in the treatment of patients with relapsed cancer Abandoned CA2805200A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1011771.1 2010-07-13
GBGB1011771.1A GB201011771D0 (en) 2010-07-13 2010-07-13 Biological material and particular uses thereof
PCT/EP2011/061983 WO2012007516A1 (en) 2010-07-13 2011-07-13 Use of antibodies against icam-1 in the treatment of patients with relapsed cancer

Publications (1)

Publication Number Publication Date
CA2805200A1 true CA2805200A1 (en) 2012-01-19

Family

ID=42712312

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2805200A Abandoned CA2805200A1 (en) 2010-07-13 2011-07-13 Use of antibodies against icam-1 in the treatment of patients with relapsed cancer

Country Status (10)

Country Link
US (2) US20130189260A1 (enExample)
EP (1) EP2593481A1 (enExample)
JP (2) JP5992406B2 (enExample)
KR (1) KR20130100977A (enExample)
CN (1) CN103003308B (enExample)
AU (1) AU2011278350B2 (enExample)
CA (1) CA2805200A1 (enExample)
GB (1) GB201011771D0 (enExample)
RU (1) RU2593709C2 (enExample)
WO (1) WO2012007516A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0525214D0 (en) 2005-12-12 2006-01-18 Bioinvent Int Ab Biological materials and uses thereof
GB2495113A (en) * 2011-09-29 2013-04-03 Bioinvent Int Ab Anti-ICAM-1 antibody for treating multiple-myeloma-related disorders
CN104936618A (zh) 2012-11-29 2015-09-23 拜尔健康护理有限责任公司 针对活化蛋白c的人源化单克隆抗体及其用途
MX2015006424A (es) * 2012-11-29 2015-08-14 Bayer Healthcare Llc Anticuerpos monoclonales contra una proteina activada c (apc).
GB201300346D0 (en) * 2013-01-09 2013-02-20 Biolnvent Internat Ab BiologIcal materials and uses thereof
US20170173005A1 (en) 2014-03-27 2017-06-22 Research Foundation Of The City University Of New York Method for detecting or treating triple negative breast cancer
KR101674874B1 (ko) 2014-10-21 2016-11-22 한국원자력의학원 항암제 내성 예측용 바이오마커로서의 ｉｃａｍ－３ 및 이의 용도
US9795624B2 (en) 2015-05-04 2017-10-24 Research Foundation Of The City University Of New York Cationic polymers as co-drugs for chemotherapeutic agents
US11077187B2 (en) 2015-11-17 2021-08-03 Oklahoma Medical Research Foundation Epitope of optimized humanized monoclonal antibodies against activated protein C and uses thereof
CA3224535C (en) * 2016-01-12 2026-03-17 University Of Southern California A diet package for a fasting mimicking and enhancing diet
KR20180136551A (ko) 2016-05-11 2018-12-24 유니버시티 오브 써던 캘리포니아 위장 자가면역/염증 질환을 위한 면역조절 치료로서의 단식 모방 식이(fmd)
US11284640B2 (en) 2017-02-14 2022-03-29 University Of Southern California Fasting mimicking diet
US11260132B2 (en) 2017-03-16 2022-03-01 Children's Medical Center Corporation Engineered liposomes as cancer-targeted therapeutics
CN109949256B (zh) * 2019-01-14 2023-04-07 昆明理工大学 一种基于傅里叶变换的天文图像融合方法
SG11202108274SA (en) 2019-02-06 2021-08-30 Venthera Inc Topical phosphoinositide 3-kinase inhibitors
JP2023535280A (ja) * 2020-07-20 2023-08-17 エフエヌシーティー バイオテック、インコーポレイテッド 大腸癌転移阻害剤をスクリーニングする方法
EP4192431A1 (en) * 2020-08-04 2023-06-14 Venthera, Inc. Formulations of phosphoinositide 3-kinase inhibitors
KR20230107115A (ko) 2022-01-07 2023-07-14 서울대학교병원 항-icam-1 항체의 단기요법을 이용한 간이식 거부반응의 억제방법
CN121399157A (zh) 2023-06-12 2026-01-23 美国安进公司 淋巴毒素β受体激动剂结合蛋白
KR20250179879A (ko) 2024-06-24 2025-12-31 서울대학교병원 항-icam-1 항체를 유효성분으로 포함하는 비알콜성 지방간 또는 비알콜성 지방간염 치료용 약학적 조성물
WO2026082770A1 (en) * 2024-10-16 2026-04-23 Bioinvent International Ab Antibodies against domain 4 of icam-1 and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
ZA883159B (en) * 1987-05-04 1990-01-31 Dana Farber Cancer Inst Inc Intercellular adhesion molecules and their binding ligands
US5643872A (en) 1989-10-23 1997-07-01 Smithkline Beecham Corporation Cyclic anti-aggregatory peptides
US6008058A (en) 1993-06-18 1999-12-28 University Of Louisville Cyclic peptide mixtures via side chain or backbone attachment and solid phase synthesis
GB9701425D0 (en) 1997-01-24 1997-03-12 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
GB0525214D0 (en) * 2005-12-12 2006-01-18 Bioinvent Int Ab Biological materials and uses thereof
EP2251694A4 (en) * 2008-02-29 2011-03-16 Univ Shinshu KIT FOR RECOGNIZING CANCER METASTASES IN KEEPER LYMPHOTIC NODES
GB0903151D0 (en) * 2009-02-25 2009-04-08 Bioinvent Int Ab Antibody uses and methods

Also Published As

Publication number Publication date
RU2593709C2 (ru) 2016-08-10
JP2013539454A (ja) 2013-10-24
AU2011278350B2 (en) 2014-03-20
KR20130100977A (ko) 2013-09-12
CN103003308A (zh) 2013-03-27
WO2012007516A1 (en) 2012-01-19
JP2016175906A (ja) 2016-10-06
AU2011278350A1 (en) 2013-01-10
US20130189260A1 (en) 2013-07-25
GB201011771D0 (en) 2010-08-25
JP5992406B2 (ja) 2016-09-14
US20160280788A1 (en) 2016-09-29
RU2013105769A (ru) 2014-08-20
EP2593481A1 (en) 2013-05-22
CN103003308B (zh) 2016-08-10

Similar Documents

Publication Publication Date Title
AU2011278350B2 (en) Use of antibodies against ICAM-1 in the treatment of patients with relapsed cancer
US9803013B2 (en) Biological materials and uses thereof
EP3344658B1 (en) Antibodies specific to human t-cell immunoglobulin and itim domain (tigit)
KR102925710B1 (ko) 림프구에서의 저해 경로의 중화
AU2018266784B2 (en) LRRC33 inhibitors and use thereof
AU2018233976A1 (en) Fc-optimized anti-CD25 for tumour specific cell depletion
Shanehbandi et al. CD20-based immunotherapy of B-cell derived hematologic malignancies
US11447549B2 (en) Combination of a Treg depleting anti-4-1BB antibody and anti-PD1 antibody
US20120087916A1 (en) Anti-icam-1 antibody, uses and methods
US20180221482A1 (en) Use of antibodies against icam-1 in combination with an anti cancer drug in the treatment of patients
RU2815066C2 (ru) Молекулы, связывающие мезотелин и cd137
CA3099260C (en) Lrrc33 inhibitors and use thereof
HK40103766A (en) Lrrc33 inhibitors and use thereof
CA3210609A1 (en) Novel combinations of antibodies and uses thereof
EA049996B1 (ru) Антитело к siglec-10 (варианты)
WO2026082770A1 (en) Antibodies against domain 4 of icam-1 and uses thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160627

FZDE Discontinued

Effective date: 20190715